These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 8254397

  • 1. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D.
    J Nucl Med; 1993 Dec; 34(12):2111-9. PubMed ID: 8254397
    [Abstract] [Full Text] [Related]

  • 2. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC.
    J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
    [Abstract] [Full Text] [Related]

  • 3. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 4. Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice.
    Goldrosen MH, Biddle WC, Pancook J, Bakshi S, Vanderheyden JL, Fritzberg AR, Morgan AC, Foon KA.
    Cancer Res; 1990 Dec 15; 50(24):7973-8. PubMed ID: 2253238
    [Abstract] [Full Text] [Related]

  • 5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 15; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 15; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 7. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P.
    Obstet Gynecol; 1993 Oct 15; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [Abstract] [Full Text] [Related]

  • 8. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 15; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec 15; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.
    Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.
    J Nucl Med; 1995 May 15; 36(5):754-61. PubMed ID: 7738644
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
    Colnot DR, Wilhelm AJ, Cloos J, Roos JC, de Bree R, Quak JJ, Snow GB, van Dongen GA.
    J Nucl Med; 2001 Sep 15; 42(9):1364-7. PubMed ID: 11535726
    [Abstract] [Full Text] [Related]

  • 12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 15; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 15; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC.
    Cancer Biother Radiopharm; 2003 Aug 15; 18(4):525-33. PubMed ID: 14503946
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 16. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.
    Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG.
    J Nucl Med; 1993 Jun 15; 34(6):908-17. PubMed ID: 8509857
    [Abstract] [Full Text] [Related]

  • 17. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB, Durham JS, Fisher DR, Weiden PL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 01; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 19. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, Rattat D, Buck A, Döhner H, Reske SN.
    Cancer Biother Radiopharm; 2002 Apr 01; 17(2):151-63. PubMed ID: 12030109
    [Abstract] [Full Text] [Related]

  • 20. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.